Your session is about to expire
← Back to Search
LM-108 for Solid Tumors
Study Summary
This trial is testing a new cancer drug, LM-108, to see if it is safe and effective. The trial will involve patients with advanced solid tumors.
- Advanced Solid Tumors
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 2 trial • 22 Patients • NCT03019640Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have received any live vaccines within the past 28 days.You have a mental health condition or disorder.You have another type of cancer that is currently being treated and may require ongoing treatment.You have a history of a weakened immune system.You currently use inhalers for asthma or other respiratory conditions.You have severe, uncontrolled pain from your tumor.You have a serious heart or blood vessel condition.You have fluid buildup around your lungs, heart, or abdomen that needs to be drained regularly and is not under control.You have a history of an autoimmune disease.You are able to perform daily activities without much difficulty.Any side effects from previous cancer treatment have not fully resolved or are still causing mild symptoms.You must have at least one visible tumor that can be measured using specific guidelines (RECIST v1.1).Your organs and bone marrow must be functioning properly based on recent lab tests taken within a week before starting the study.You have a known condition where the central nervous system (brain and spinal cord) is affected.You have a type of cancer that has come back or is not responding to standard treatments. Your doctor has confirmed this through a biopsy or other testing.
- Group 1: LM-108 Dose Escalation
- Group 2: LM-108 Combination Dose Escalation
- Group 3: LM-108 Combination Dose Expansion
- Group 4: LM-108 Dose Expansion
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this trial enrolling participants at present?
"Affirmative. Clinicaltrials.gov shows that this study is actively inviting participants, having been posted on May 26th 2022 and most recently edited on the 29th of the same month. This trial requires 54 test subjects to be recruited from 6 different sites."
How many facilities are actively administering this experiment?
"This clinical trial is recruiting from 6 different locations; three of which are Cincinnati, Dallas and Indianapolis. To minimize the amount of travel required to partake in this study, it may be wise to select a site closest to you."
How many applicants are being accepted for inclusion in this experiment?
"54 qualified patients are necessary for the successful completion of this research, which is being carried out by LaNova Medicines Limited across multiple sites such as The Christ Hospital in Cincinnati and Mary Crowley Cancer Research in Dallas."
Who else is applying?
What state do they live in?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger